Reducing IRF4, DUSP22, or FLJ43663 polypeptide expression
Patent Number: US8679743
Executive Summary:
General Description:
T-cell lymphomas are aggressive cancers that cause death in most affected patients despite treatment with traditional chemotherapy. Peripheral T-cell lymphomas (PTCLs), in which abnormal T-lymphocytes are found in the lymph nodes, body organs, and sometimes in the peripheral circulating blood and/or bone marrow, represent 10% of non-Hodgkin lymphomas. PTCLs are fatal in most patients. In some cases, agents that inhibits the expression of an IRF4 polypeptide, DUSP22 polypeptide and/or an FLJ43663 polypeptide can be used to reduce the proliferation of abnormal T-lymphocytes (e.g., T-cell lymphomas). The IRF4 polypeptide inhibitor can be an siRNA molecule capable of inducing RNA interference against mRNA encoding an IRF4 polypeptide. The DUSP22 polypeptide inhibitor can be an siRNA molecule capable of inducing RNA interference against mRNA encoding an DUSP22 polypeptide. The FLJ43663 polypeptide inhibitor can be an siRNA molecule capable of inducing RNA interference against mRNA encoding an FLJ43663 polypeptide.
Strengths:
Weaknesses:
Patent Status:
Inventor Bio: Andrew L. Feldman
http://www.mayo.edu/research/faculty/feldman-andrew-l-m-d/bio-00086112
Executive Summary:
- Invention Type: Therapeutic
- Patent Status: Granted (Grant date: 2014-03-25)
- Patent Link: https://patents.google.com/patent/US8679743/
- Research Institute: Mayo Clinic
- Disease Focus: T-cell lymphomas
- Basis of Invention: Methods and materials involved in reducing the expression of IRF4 polypeptide and reducing DUSP22 or FLJ43663 polypeptide activity in T-cell lymphomas
- How it works: Near-infrared light will trigger a conformational change of the lipid bilayer to release the encapsulated therapeutic agent to the desired location
- Lead Challenge Inventor: Andrew L. Feldman
- Inventors: Feldman; Andrew L. (Rochester, MN), Dogan; Ahmet (Rochester, MN), Vasmatzis; George (Oronoco, MN), Law; Mark (Rochester, MN), Smith; David I. (Rochester, MN)
- Development Stage: Patient data on diagnostics, in vitro data on therapy
- Novelty:
- No similar siRNA drugs exist in the market yet. Diagnostic potential (immunohistology)
- Clinical Applications:
- Inhibiting expression of IRF4 polypeptide, DUSP22 polypeptide and/or an FLJ43663 polypeptide. These inhibitors may reduce the proliferation of abnormal T-lymphocytes
General Description:
T-cell lymphomas are aggressive cancers that cause death in most affected patients despite treatment with traditional chemotherapy. Peripheral T-cell lymphomas (PTCLs), in which abnormal T-lymphocytes are found in the lymph nodes, body organs, and sometimes in the peripheral circulating blood and/or bone marrow, represent 10% of non-Hodgkin lymphomas. PTCLs are fatal in most patients. In some cases, agents that inhibits the expression of an IRF4 polypeptide, DUSP22 polypeptide and/or an FLJ43663 polypeptide can be used to reduce the proliferation of abnormal T-lymphocytes (e.g., T-cell lymphomas). The IRF4 polypeptide inhibitor can be an siRNA molecule capable of inducing RNA interference against mRNA encoding an IRF4 polypeptide. The DUSP22 polypeptide inhibitor can be an siRNA molecule capable of inducing RNA interference against mRNA encoding an DUSP22 polypeptide. The FLJ43663 polypeptide inhibitor can be an siRNA molecule capable of inducing RNA interference against mRNA encoding an FLJ43663 polypeptide.
Strengths:
- No similar siRNA drugs exist on the market yet. Diagnostic potential (immunohistology)
- High specificity for anaplastic large cell lymphoma
Weaknesses:
- siRNA-based therapies have encountered many obstacles in clinical trials, including the stability of the RNA molecule itself, minimization of nonspecific inflammation, controlled release of the RNA molecule, and specificity and efficiency of the delivery vehicles
Patent Status:
- Priority date: 2009-05-18
- Filing date: 2011-08-19
- Publication date: 2014-03-25
- Grant date: 2014-03-25
Inventor Bio: Andrew L. Feldman
http://www.mayo.edu/research/faculty/feldman-andrew-l-m-d/bio-00086112
